

## Commercial/Healthcare Exchange PA Criteria

Effective: August 14<sup>th</sup>, 2019

**Prior Authorization:** Sunosi

**Products Affected:** Sunosi (solriamfetol) tablet

**Medication Description:** Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

**Covered Uses:**

1. Excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

**Exclusion Criteria:** Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days.

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried and failed

**Age Restrictions:** 18 years of age or older

**Prescriber Restrictions:** Prescribed by or in consultation with a sleep disorder specialist, psychiatrist, or neurologist

**Coverage Duration:** 12 months

**Other Criteria:**

**Excessive daytime sleepiness associated with narcolepsy**

- A. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy; **AND**
- B. Patient must have a trial and failure, contraindication, or intolerance to one CNS stimulant drug (e.g., methylphenidate, dexamethylphenidate, dextroamphetamine) **AND** one CNS wakefulness promoting drug (e.g. armodafinil).

**Excessive daytime sleepiness associated with obstructive sleep apnea (OSA)**

- A. Patient has a diagnosis of excessive daytime sleepiness associated with obstructive sleep apnea (OSA); **AND**
- B. Patient's underlying airway obstruction has been treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating Sunosi; **AND**
- C. Sunosi will be used in conjunction with continuous positive airway pressure (CPAP); **OR**
- D. The patient is unable to initiate or tolerate CPAP therapy; **AND**
- E. Patient must have a trial and failure, contraindication, or intolerance to armodafinil or modafinil.

**References:**

1. Sunosi<sup>TM</sup> tablets [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; March 2019.
2. National Institutes of Health. Narcolepsy Fact Sheet. National Institute of Neurological Disorders and Stroke. Date last modified: July, 6, 2018. Available at: <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet>. Accessed on July 31, 2019.

3. Mayo Clinic. Obstructive sleep apnea. Available at: <https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090?p=1>. Accessed on July 31, 2019.
4. Provigil® tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2018.
5. Nuvigil® tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2018.
6. Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. *Sleep Med Rev.* 2019;43:23-36.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	08/12/2019